Impetigo Global Market Report 2025

Impetigo is a highly contagious bacterial skin infection primarily caused by *Streptococcus pyogenes*. It typically appears as red sores or blisters that break open, ooze, and develop a yellowish-brown crust. The infection spreads easily through direct skin-to-skin contact or by touching contaminated surfaces.

The primary treatment options for impetigo include topical antibiotics, oral antibiotics, and antiseptic soaks. Oral antibiotics, available in pill or liquid form, are typically prescribed for more severe or widespread infections. The infection can be caused by various pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and other bacteria, with severity ranging from mild to moderate to severe. Impetigo affects different age groups, including children, adults, and the elderly.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The impetigo market research report is one of a series of new reports from The Business Research Company that provides impetigo market statistics, including impetigo industry global market size, regional shares, competitors with an impetigo market share, detailed impetigo market segments, market trends, and opportunities, and any further data you may need to thrive in the impetigo industry. This impetigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The impetigo market size has grown strongly in recent years. It will grow from $2.25 billion in 2024 to $2.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising incidence of skin infections, healthcare infrastructure improvements, increased access to telemedicine, increase in public funding for infectious diseases, growing demand for topical treatments.

The impetigo market size is expected to see strong growth in the next few years. It will grow to $3.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growth in telemedicine and E-pharmacy, government and private sector initiatives, rising prevalence of skin infections, pediatric population growth, growing demand for dermatology clinics. Major trends in the forecast period include advancements in topical treatments, introduction of novel antimicrobial agents, strategic collaborations and partnerships, regulatory approvals and pipeline advancements.

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. antibiotic supply chains by increasing costs for topical mupirocin and oral cephalexin imported from India and Canada, potentially prolonging bacterial skin infections and raising pediatric dermatology expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of skin infections is driving the expansion of the impetigo market. Skin infections occur when harmful microorganisms such as bacteria, viruses, fungi, or parasites invade the skin, leading to irritation, inflammation, or other symptoms. Several factors contribute to the rising occurrence of skin infections, including antibiotic resistance, poor hygiene, climate change, weakened immune systems, and increased global travel. Impetigo treatment plays a crucial role in managing the infection by targeting bacterial pathogens, primarily Streptococcus or Staphylococcus species, using topical or oral antibiotics. This helps alleviate symptoms such as itching and discomfort, prevents the infection from spreading, and accelerates healing, reducing the risk of complications and recurrence. For example, in September 2024, GOV.UK, a UK-based government agency, reported 13,912 cases of Staphylococcus aureus bacteremia during the 2022-2023 financial year, an increase of 7.2% compared to the previous year. As a result, the growing prevalence of skin infections is fueling the demand for impetigo treatments.

The expansion of healthcare facilities is another key driver of the impetigo market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide essential medical services to patients. Several factors are contributing to the improvement of healthcare infrastructure, such as increased investments, patient-centered care initiatives, population growth, and aging demographics. Enhanced healthcare facilities support impetigo management by providing better access to specialized dermatological care, expanding the availability of effective treatment options, promoting hygiene practices to prevent infection spread, and enabling early diagnosis and timely intervention. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the United States had 6,129 hospitals, reflecting a 0.59% increase from the previous year. As healthcare facilities improve, the accessibility and effectiveness of impetigo treatment continue to grow.

The rise in healthcare spending is also a significant factor in the expansion of the impetigo market. Healthcare spending includes expenditures on medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, all of which contribute to improving individual and public health. Increased healthcare spending is driven by an aging population, advancements in medical technology, a rising prevalence of chronic diseases, and growing demand for healthcare services. In the context of impetigo, higher healthcare expenditure supports the development of innovative treatments, improves access to critical care products, and enhances patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that UK healthcare spending grew by 5.6% between 2022 and 2023, compared to just 0.9% in 2022. The total healthcare expenditure in the UK reached approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare spending is further accelerating the growth of the impetigo market.

Major players in the impetigo market are Roche Holding AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Galderma SA, Shionogi & Co. Ltd., Dr. Reddy's Laboratories Ltd., Leo Pharma A/S, Torrent Pharmaceuticals Ltd., Almirall S.A, Taro Pharmaceutical Industries Ltd., BioCryst Pharmaceuticals Inc., Melinta Therapeutics Inc., Cutanea Life Sciences Inc., InfectoPharm Arzneimittel und Consilium GmbH, Medimetriks Pharmaceuticals Inc., NovaBay Pharmaceuticals Inc., Ferrer Internacional S.A.

North America was the largest region in the impetigo market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in impetigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the impetigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The impetigo treatment market consists of sales of non-bullous impetigo, and bullous impetigo. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Impetigo Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on impetigo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for impetigo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The impetigo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Topical Antibiotics; Oral Antibiotics; Antiseptic Soaks
• 2) By Causative Pathogen: Staphylococcus aureus; Streptococcus pyogenes; Other Bacteria
• 3) By Severity: Mild; Moderate; Severe
• 4) By Patient Age: Children; Adults; Elderly
• Subsegments:
• 1) By Topical Antibiotics: Mupirocin; Retapamulin; Fusidic Acid
• 2) By Oral Antibiotics: Cephalexin; Dicloxacillin; Clindamycin
• 3) By Antiseptic Soaks: Chlorhexidine; Hydrogen Peroxide; Potassium Permanganate
• Companies Mentioned: Roche Holding AG; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Galderma SA; Shionogi & Co. Ltd.; Dr. Reddy's Laboratories Ltd.; Leo Pharma A/S; Torrent Pharmaceuticals Ltd.; Almirall S.A; Taro Pharmaceutical Industries Ltd.; BioCryst Pharmaceuticals Inc.; Melinta Therapeutics Inc.; Cutanea Life Sciences Inc.; InfectoPharm Arzneimittel und Consilium GmbH; Medimetriks Pharmaceuticals Inc.; NovaBay Pharmaceuticals Inc.; Ferrer Internacional S.A
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.